Morphine withdrawal increases metabotropic glutamate 2/3 receptors expression in nucleus accumbens

NeuroReport

Volumn 19, Issue 9, 2008, Pages 911-914

  Modafferi, Antonella M E ^a   Diana, Marco ^b   Nicoletti, Ferdinando ^a,c   Scaccianoce, Sergio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

Caudate putamen; Drug addiction; Metabotropic glutamate receptors; Morphinewithdrawal; Nucleus accumbens

Indexed keywords

METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; MORPHINE; METABOTROPIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG WITHDRAWAL; LONG TERM CARE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR DENSITY; SYMPTOM; TREATMENT DURATION; WESTERN BLOTTING; ANIMAL; CLASSIFICATION; DOSE RESPONSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME; WITHDRAWAL SYNDROME;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MALE; MORPHINE; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 52249084594     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e3283021cc0     Document Type: Article

References (25)

1. Melis M, Spiga S, Diana M. The dopamine hypothesis of drug addiction: hypodopaminergic state. Int Rev Neurobiol 2005; 63:101-154.
2. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001; 2:119-128.
3. Hyman SE, Malenka RC. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2001; 2:695-703.
4. Pulvirenti L, Diana M. Drug dependence as a disorder of neural plasticity: focus on dopamine and glutamate. Rev Neurosci 2001; 12:141-158.
5. Kenny PJ, Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 2004; 25:265-272.
6. Kenny PJ, Paterson NE, Boutrel B, Semenova S, Harrison AA, Gasparini F, et al. Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats. Ann N Y Acad Sci 2003; 1003:415-418.
7. Paterson NE, Semenova S, Gasparini F, Markou A. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology 2003; 167:257-264.
8. Vandergriff J, Rasmussen K. The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioural signs of morphine withdrawal. Neuropharmacology 1999; 38:217-222.
9. Rasmussen K, Hsu MA, Vandergriff J. The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons. Neuropharmacology 2004; 46:620-628.
10. Cho K, Bashir ZI. Cooperation between mglu receptors: a depressing mechanism? Trends Neurosci 2002; 25:405-411.
11. 2+ channels in metabotropic glutamate receptor 2/3-dependent presynaptic long-term depression at nucleus accumbens synapses. J Neurosci 2002; 22:4346-4356.
12. Robbe D, Bockaert J, Manzoni OJ. Metabotropic glutamate receptor 2/3-dependent long-term depression in the nucleus accumbens is blocked in morphine withdrawn mice. Eur J Neurosci 2002; 16:2231-2235.
13. Acquas E, Di Chiara G. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J Neurochem 1992; 58:1620-1625.
14. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Academic Press: San Diego; 1998.
15. Storto M, de Grazia U, Knöpfel T, Canonico PL, Copani A, Richelmi P, et al. Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage. Hepatology. 2000; 31:649-655.
16. Storto M, Sallese M, Salvatore L, Poulet R, Condorelli DF, Dell'Albani P, et al. Expression of metabotropic glutamate receptors in the rat and human testis. J Endocrinol 2001; 170:71-78.
17. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Storto M, Fornai F, et al. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci 2004; 24:828-835.
18. Aoki T, Narita M, Shibasaki M, Suzuki T. Metabotropic glutamate receptor 5 localized in the limbic forebrain is critical for the development of morphine-induced rewarding effect in mice. Eur J Neurosci 2004; 20:1633-1638.
19. Smith FL, Smith PA, Dewey WL, Javed RR. Effects of mGlu1 and mGlu5 metabotropic glutamate antagonists to reverse morphine tolerance in mice. Eur J Pharmacol 2004; 492:137-142.
20. Rasmussen K, Martin H, Berger JE, Seager MA. The mGlu5 receptor antagonists MPEP and MTEP attenuate behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons in rats. Neuropharmacology 2005; 48:173-180.
21. Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 2000; 75:889-907.
22. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci 1998; 18:9594-9600.
23. D'Onofrio M, Cuomo L, Battaglia G, Ngomba RT, Storto M, Kingston AE, et al. Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J Neurochem 2001; 78:435-445.
24. Matarredona ER, Santiago M, Venero JL, Cano J, Machado A. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurochem 2001; 76: 351-360.
25. Hatami H, Oryan S, Semnanian S, Kazemi B, Bandepour M, Ahmadiani A. Alterations of BDNF and NT-3 genes expression in the nucleus paragigantocellularis during morphine dependency and withdrawal. Neuropeptides 2007; 41:321-328.